tirzepatide and lamotrigine Never accelerate titration (and know the UGT interactions) FDA Approves Tirzepatide, A Potential

This pathway is also relevant for Medicare Part D: the Treat and Reduce Obesity Act, signed into law in late 2025, requires Part D plans to cover at least one FDA-approved anti-obesity medication effective April 2026, and Wegovy's CV indication may offer an even earlier coverage pathway for beneficiaries with established heart disease

The Takeaway: GLP-1s Are a Tool, Not a Fix-All Speak with your healthcare provider before starting any new medication

& Savour, A

Many people drink less when theyre eating less, and nausea or constipation can reduce thirst motivation. If vomiting or diarrhoea occurs, dehydration risk increases and that can feel like fatigue, dizziness, or brain fog

Interestingly, tirzepatide may offer slightly better tolerability for some individuals because of its dual GLP-1/GIP action

without a prescription